EDIT
Editas Medicine, Inc. Healthcare Biotechnology
5/12
Innovation Score
Patent Activity
3/3
23 patents found
FUZZY
Cash Runway
0/3
11 months of cash remaining based on current burn rate.
Cash on hand: $123.6M
Cash on hand: $123.6M
Revenue Trajectory
0/3
Revenue: $38.7M
YoY Growth: -39.2%
YoY Growth: -39.2%
Management Quality
2/3
Insider ownership: 0.3%
SBC/Revenue: 0.0%
No reverse splits detected
SBC/Revenue: 0.0%
No reverse splits detected
Key Metrics
Market Cap
$304.5M
Revenue
$38.7M
Revenue Growth (YoY)
-39.2%
Cash on Hand
$123.6M
Cash Runway
11 months
Shares Outstanding
97.9M
Insider Ownership
0.3%
SBC / Revenue
0.0%
Sector / Industry
Healthcare / Biotechnology
Patents (23)
Match type: FUZZY — company name matched partially; verify assignee
- Systems and methods for the treatment of hemoglobinopathies
- Assessing nuclease cleavage
- CRISPR/Cas-related methods and compositions for treating Leber's congenital amaurosis 10 (LCA10)
- Crispr/CAS-related methods and compositions for treating primary open angle glaucoma
- Methods of assessing nuclease cleavage
7-Step Risk Assessment
How EDIT maps to our micro cap methodology:
- Innovation Signal 23 patents identified. This suggests the company is investing in defensible IP.
- Cash Runway Check 11 months of runway. Short runway increases dilution risk — watch for capital raises.
- Revenue Trajectory -39.2% YoY growth on $38.7M revenue. Revenue declining — investigate whether this is temporary or structural.
- Management Alignment Insiders hold 0.3% of shares. SBC is 0.0% of revenue.
- Competitive Moat Review the company's 10-K for barriers to entry: patents, network effects, switching costs, regulatory approvals. This step requires manual research.
- Catalyst Identification Look for upcoming catalysts: FDA decisions, contract wins, product launches, partnerships. Check recent 8-K filings and earnings transcripts.
- Position Sizing Micro caps carry outsized risk. Consider position sizing relative to conviction level and portfolio concentration. This is a $304.5M company.
Financial Detail
Free Cash Flow
$-73.8M
FCF Yield
-24.2%
Return on Equity
-326.1%
Debt / Equity
392.4%
Gross Margin
-109.2%
Profit Margin
-281.6%
Operating Margin
-883.2%
Price / Book
69.11
Current Ratio
3.22
Dividend Yield
None
Share Count Change (YoY)
N/A
Share Count Change (3yr)
N/A
Free Cash Flow Trend
Insufficient Data
Consecutive Years FCF Positive
0
Disclaimer: This is an automated screening tool, not investment advice. Micro cap stocks are inherently risky with low liquidity and high volatility. The innovation score is based on publicly available data and may not reflect the full picture. Steps 5-7 of the methodology require your own research. See our full disclaimer.
Last screened: 2026-05-11